Fed Circ rules on interim USPTO commissioner reviews
Apple and Intel weigh in on SCOTUS Arthrex review
Federal Circuit refuses Arthrex rerun, prerogative now with SCOTUS
Mark Van Scyoc / Shutterstock.com
Early signs show that US v Arthrex is unlikely to herald a spate of inter partes reviews, but may fuel uncertainty around the scope of the acting USPTO director’s role, lawyers have told WIPR.
The rest of this article is locked for subscribers only. Please login to continue reading.
If you don't have a login, you will need to purchase a subscription to gain access to this article, including all our online content. Please use this link and follow the steps.
For multi-user price options, or to check if your company has an existing subscription to us that we can add you to for FREE, please email Atif Choudhury at email@example.com
Arthrex, SCOTUS, Drew Hirshfeld, USPTO, patents